Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. It is of important significance to find biomarkers for the prognostic monitoring of HCC. The 14-3-3s and EZH2 proteins are involved in cell cycle regulation and epigenetic silencing. We herein examined the significance of 14-3-3 s and EZH2 in HCC (n = 167) by immunohistochemistry, RT-PCR and qRT-PCR. The correlation between 14-3-3s and EZH2 expression and patients ’ clinicopathologic features were examined, as was the correlation between 14-3-3s and EZH2 expression and the prognosis of HCC patients. We found that 14-3-3s and EZH2 were highly expressed in HCC (71 % and 90%), the expression of EZH2, but not 14-3-3s, is associated with vascular invasion and tumor ...
Alterations of polycomb group (PcG) genes directly modulate the trimethylation of histone H3 lysine ...
Global changes in the epigenome are increasingly being appreciated as key events in cancer progressi...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...
The enhancer of zeste homolog 2 (EZH2) plays a critical role in different components of anti-tumor i...
Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated...
<p>(A) 14-3-3σ was strong stained in hepatocellular carcinoma tissue, (B) nearly negative expression...
The enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the catalytic comp...
Background: The enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the ca...
<p>(A) The expression of 14-3-3σ and EZH2 was detected by RT-PCR, C: Cancer tissue, N: Noncancerous ...
Enhancer of zeste homolog 2 (EZH2) is suggested to be a potential therapeutic target and a diagnosti...
Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesi...
The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported t...
Background: 14-3-3 epsilon is implicated in regulating tumor progression, including hepatocellular c...
Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during c...
Background & AimsAberrant chromatin modification is a key feature of hepatocellular carcinoma (HCC),...
Alterations of polycomb group (PcG) genes directly modulate the trimethylation of histone H3 lysine ...
Global changes in the epigenome are increasingly being appreciated as key events in cancer progressi...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...
The enhancer of zeste homolog 2 (EZH2) plays a critical role in different components of anti-tumor i...
Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated...
<p>(A) 14-3-3σ was strong stained in hepatocellular carcinoma tissue, (B) nearly negative expression...
The enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the catalytic comp...
Background: The enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the ca...
<p>(A) The expression of 14-3-3σ and EZH2 was detected by RT-PCR, C: Cancer tissue, N: Noncancerous ...
Enhancer of zeste homolog 2 (EZH2) is suggested to be a potential therapeutic target and a diagnosti...
Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesi...
The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported t...
Background: 14-3-3 epsilon is implicated in regulating tumor progression, including hepatocellular c...
Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during c...
Background & AimsAberrant chromatin modification is a key feature of hepatocellular carcinoma (HCC),...
Alterations of polycomb group (PcG) genes directly modulate the trimethylation of histone H3 lysine ...
Global changes in the epigenome are increasingly being appreciated as key events in cancer progressi...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...